- Home
- RIVN vs INSM Comparison
RIVN vs INSM Comparison
Compare RIVN & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIVN
- INSM
- Stock Information
- Founded
- RIVN 2009
- INSM 1988
- Country
- RIVN United States
- INSM United States
- Employees
- RIVN N/A
- INSM N/A
- Industry
- RIVN Auto Manufacturing
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- RIVN Consumer Discretionary
- INSM Health Care
- Exchange
- RIVN Nasdaq
- INSM Nasdaq
- Market Cap
- RIVN 13.3B
- INSM 13.5B
- IPO Year
- RIVN 2021
- INSM 2000
- Fundamental
- Price
- RIVN $13.51
- INSM $73.26
- Analyst Decision
- RIVN Buy
- INSM Strong Buy
- Analyst Count
- RIVN 23
- INSM 16
- Target Price
- RIVN $17.86
- INSM $81.86
- AVG Volume (30 Days)
- RIVN 24.6M
- INSM 2.2M
- Earning Date
- RIVN 11-05-2024
- INSM 10-24-2024
- Dividend Yield
- RIVN N/A
- INSM N/A
- EPS Growth
- RIVN N/A
- INSM N/A
- EPS
- RIVN N/A
- INSM N/A
- Revenue
- RIVN $5,014,000,000.00
- INSM $328,605,000.00
- Revenue This Year
- RIVN $10.35
- INSM $19.10
- Revenue Next Year
- RIVN $24.03
- INSM $44.67
- P/E Ratio
- RIVN N/A
- INSM N/A
- Revenue Growth
- RIVN 68.20
- INSM 21.94
- 52 Week Low
- RIVN $8.26
- INSM $21.92
- 52 Week High
- RIVN $24.87
- INSM $80.53
- Technical
- Relative Strength Index (RSI)
- RIVN 44.53
- INSM 52.70
- Support Level
- RIVN $12.81
- INSM $70.63
- Resistance Level
- RIVN $14.08
- INSM $74.93
- Average True Range (ATR)
- RIVN 0.70
- INSM 2.47
- MACD
- RIVN 0.03
- INSM -0.21
- Stochastic Oscillator
- RIVN 23.50
- INSM 58.63
About RIVN Rivian Automotive Inc.
Rivian Automotive Inc designs, develops, and manufactures category-defining electric vehicles and accessories. In the consumer market, the company launched the R1 platform with the first generation of consumer vehicles: the R1T, a two-row, five-passenger pickup truck, and the R1S, a three-row, seven-passenger sport utility vehicle (SUV).
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.